ImmuPharma PLC (LON:IMM) has begun dosing its first patients in the phase-III trial of its flagship drug Lupuzor for the hard-to-treat autoimmune disease Lupus. In all 200 people will take part in the study, which is being carried out over 10 centres in the States and 35 in Europe, and Chairman Tim McCarthy tells Proactive Investors recruitment is “going well”. He expects all the necessary patients to be recruited this year, with the trial to be… Read More
Read Panmure Gordon & Co's note on IMMUPHARMA PLC (IMM), out this morning, by visiting https://www.research-tree.com/company/GB0033711010 "This morning ImmuPharma has released prelims for the year-ending 31 December 2015. Today’s numbers reflect a business in development-phase – the pivotal phase III study for Lupuzor™ now having commenced – with the fund-raising process (£8.4m fundraising and EIS/VCT qualifying status) having been completed after the… Read More
Read Northland Capital Partners's note on IMMUPHARMA PLC (IMM), out this morning, by visiting https://www.research-tree.com/company/GB0033711010 "ImmuPharma continues to progress its lead clinical programme, with recruitment in the Lupuzor Phase III trial going to plan. The group’s key objective this year is to complete the recruitment of 200 Lupus patients. Top line results from the trial are expected to be announced by the end of 2017..."
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.